Institution
École Polytechnique Fédérale de Lausanne
Facility•Lausanne, Switzerland•
About: École Polytechnique Fédérale de Lausanne is a facility organization based out in Lausanne, Switzerland. It is known for research contribution in the topics: Population & Catalysis. The organization has 44041 authors who have published 98296 publications receiving 4372092 citations. The organization is also known as: EPFL & ETHL.
Topics: Population, Catalysis, Laser, Thin film, Perovskite (structure)
Papers published on a yearly basis
Papers
More filters
••
TL;DR: An analysis of 134 industrial biotransformations reveals that hydrolases and redox biocatalysts are the most prominent categories and the implications of this for future research and development onBiocatalysis are discussed.
692 citations
••
TL;DR: The experimental evidence for the proposed mode of action of this coordination compound is discussed, including transport into the cell via the transferrin cycle and activation by reduction.
Abstract: The promising drug candidate indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) is the second Ru-based anticancer agent to enter clinical trials. In this review, which is an update of a paper from 2006 (Hartinger et al., J. Inorg. Biochem. 2006, 100, 891-904), the experimental evidence for the proposed mode of action of this coordination compound is discussed, including transport into the cell via the transferrin cycle and activation by reduction. The results of the early clinical development of KP1019 are summarized in which five out of six evaluated patients experienced disease stabilization with no severe side effects.
691 citations
••
689 citations
••
TL;DR: In this article, the authors focus on the analysis of energy savings that can be achieved in a building heating system by applying model predictive control (MPC) and using weather predictions.
689 citations
••
TL;DR: A new approach for the automated design of ligands against profiles of multiple drug targets, demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug into brain-penetrable ligands with either specific polypharmacology or exquisite selectivity profiles for G-protein-coupled receptors is described.
Abstract: The clinical efficacy and safety of a drug is determined by its activity profile across many proteins in the proteome. However, designing drugs with a specific multi-target profile is both complex and difficult. Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery. Here we describe a new approach for the automated design of ligands against profiles of multiple drug targets. The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug into brain-penetrable ligands with either specific polypharmacology or exquisite selectivity profiles for G-protein-coupled receptors. Overall, 800 ligand-target predictions of prospectively designed ligands were tested experimentally, of which 75% were confirmed to be correct. We also demonstrate target engagement in vivo. The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacology.
688 citations
Authors
Showing all 44420 results
Name | H-index | Papers | Citations |
---|---|---|---|
Michael Grätzel | 248 | 1423 | 303599 |
Ruedi Aebersold | 182 | 879 | 141881 |
Eliezer Masliah | 170 | 982 | 127818 |
Richard H. Friend | 169 | 1182 | 140032 |
G. A. Cowan | 159 | 2353 | 172594 |
Ian A. Wilson | 158 | 971 | 98221 |
Johan Auwerx | 158 | 653 | 95779 |
Menachem Elimelech | 157 | 547 | 95285 |
A. Artamonov | 150 | 1858 | 119791 |
Melody A. Swartz | 148 | 1304 | 103753 |
Henry J. Snaith | 146 | 511 | 123155 |
Kurt Wüthrich | 143 | 739 | 103253 |
Richard S. J. Frackowiak | 142 | 309 | 100726 |
Jean-Paul Kneib | 138 | 805 | 89287 |
Kevin J. Tracey | 138 | 561 | 82791 |